Loading…
Modernizing Drug Enforcement Act of 2018
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
80pct
46d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Modernizing Drug Enforcement Act of 2018 This bill deems a drug or substance that acts as an opioid mu receptor agonist (e.g., morphine) to be in schedule I of the Controlled Substances Act, subject to certain exceptions. A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2018 · fourth_quarter · Health Issues
Public Law 115-245, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, FY2019, Provisions relating to NIH, and drug abuse and treatment Drug abuse research and treatment related issues: H.R.1732, Synthetic Drug Control Act of 2017 H.R.2851/S.1327, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (SITSA) H.R.3391, Medical Marijuana Research Act of 2017 H.R.4825/S.1803, Marijuana Effective Drug Studies (MEDS) Act of 2017 S.2260, Opioids and STOP Pain Initiative Act S.2004, Combating the Opioid Epidemic Act H.R.5298, Modernizing Drug Enforcement Act of 2018 Public Law 115-271, SUPPORT for Patients and Communities Act S.1276, Cannabidiol Research Expansion Act H.R.5634, Medical Cannabis Research Act of 2018 Public Law 115-334, Agriculture Improvement Act of 2018, Hemp related provision
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2018 · fourth_quarter · Health Issues
H.R. 5298, Modernizing Drug Enforcement Act of 2018.
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, FY2019, Provisions relating to NIH, and drug abuse and treatment Drug abuse research and treatment related issues: H.R.1732, Synthetic Drug Control Act of 2017 H.R.2851/S.1327, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (SITSA) H.R.3391, Medical Marijuana Research Act of 2017 S.1803, Marijuana Effective Drug Studies (MEDS) Act of 2017 S.2260, Opioids and STOP Pain Initiative Act S.2004, Combating the Opioid Epidemic Act H.R.5298, Modernizing Drug Enforcement Act of 2018 H.R.5311/S.2456, Comprehensive Addiction and Recovery Act or CARA 2.0 Act of 2018 H.R.6, SUPPORT for Patients and Communities Act S.1276, Cannabidiol Research Expansion Act Marijuana and Cannabidiol Research Expansion Act H.R.5634, Medical Cannabis Research Act of 2018
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2018 · third_quarter · Alcohol and Drug Abuse
S. 1327, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R. 2851, (SISTA Act) Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 H.R.993, Opioid Abuse Prevention and Treatment Act of 2017 H.R. 1732, Synthetic Drug Control Act of 2017 H.R.5298, Modernizing Drug Enforcement Act of 2018
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
H.R. 5298, Modernizing Drug Enforcement Act of 2018.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
H.R. 5298, Modernizing Drug Enforcement Act of 2018.
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
S.3158, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2019, provisions relating to NIH and drug abuse and treatment Drug abuse research and treatment related issues: H.R.1732, Synthetic Drug Control Act of 2017 H.R.2851/S.1327, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (SITSA) H.R.3391, Medical Marijuana Research Act of 2017 S.1803, Marijuana Effective Drug Studies (MEDS) Act of 2017 S.2260, Opioids and STOP Pain Initiative Act S.2004, Combating the Opioid Epidemic Act H.R.5298, Modernizing Drug Enforcement Act of 2018 H.R.5311/S.2456, Comprehensive Addiction and Recovery Act or CARA 2.0 Act of 2018 H.R.6, SUPPORT for Patients and Communities Act S.1276, Cannabidiol Research Expansion Act Marijuana and Cannabidiol Research Expansion Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2018 · second_quarter · Health Issues
H.R. 5298, Modernizing Drug Enforcement Act of 2018.
Client expense: Not reported · Firm income: Not reported
2018 · first_quarter · Health Issues
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2019, provisions relating to NIH and drug abuse and treatment Drug abuse research and treatment related issues: H.R.1732, Synthetic Drug Control Act of 2017 H.R.2851/S.1327, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (SITSA) H.R.3391, Medical Marijuana Research Act of 2017 S.2004, Combating the Opioid Epidemic Act S.1803, Marijuana Effective Drug Studies (MEDS) Act of 2017 S.2260, Opioids and STOP Pain Initiative Act S.2004, Combating the Opioid Epidemic Act H.R.5298, Modernizing Drug Enforcement Act of 2018 H.R.5311/S.2456, Comprehensive Addiction and Recovery Act or CARA 2.0 Act of 2018
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2018 · first_quarter · Health Issues
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018 (H.R. 5247); Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (H.R. 2851/S. 1327); Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051) and CREATES Act (H.R. 2212/S. 974); Synthetic Drug Control Act of 2017 (H.R. 1732); Modernizing Drug Enforcement Act of 2018 (H.R. 5298) The Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 (H.R. 5202); The Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act (i.e., the "SCREEN Act")(H.R. 5228); Opioid Crisis Response Act of 2018; House opioids legislation discussion drafts on FDA Long-term Efficacy, FDA Misuse/Abuse, FDA Packaging and Disposal, FDA Accelerated Approval and Breakthrough Therapy Status, and FDA and International Mail; Drug importation; Expanding Access to Low Cost Generic Drugs Act (S. 2476); Preserve Access to Affordable Generics Act (S. 124); 180-day exclusivity; Over-the-Counter Drug Safety, Innovation, and Reform Act (S. 2315); Improving Access To Affordable Prescription Drugs Act (S. 771/H.R. 1776); Legislation on drug labeling.
Client expense: Not reported · Firm income: $310,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE